Skip to content

Study on the clinical effect and mechanism of Wuwei Baogan Pill in treating nonalcoholic fatty liver disease

Study on the clinical effect and mechanism of Wuwei Baogan Pill in treating nonalcoholic fatty liver disease

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000036882
Enrollment
Unknown
Registered
2020-08-25
Start date
2020-09-01
Completion date
Unknown
Last updated
2020-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-alcoholic fatty liver disease

Interventions

Sponsors

Qingdao Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: According to the guidelines for the diagnosis and treatment of non-alcoholic fatty liver disease (fatty liver and alcoholic liver disease Group of The Chinese Medical Association), the diagnostic criteria for non-alcoholic fatty liver disease and the TCM diagnosis are in line with the criteria for the syndrome of liver stagnation and spleen deficiency mainly combined with liver and kidney Yin deficiency and blood stasis blocking collateral.

Exclusion criteria

Exclusion criteria: 1. Hepatitis virus marker positive; 2. Patients with other serious cardiovascular, liver, kidney, lung, brain and blood system diseases; 3. Allergic constitution or allergic to this drug; 4. Have used other drugs to treat alcoholic fatty liver disease within one month; 5. Pregnant or lactating women, psychopaths.

Design outcomes

Primary

MeasureTime frame
liver function;color ultrasound;TCM syndrome score;

Countries

China

Contacts

Public ContactWang Yipeng

Department of Hepatobiliary Medicine, Qingdao Haici Medical Group

benlu.96@163.com+86 15954805656

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026